Infusion Pumps — CPB 0161 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0161 covering infusion pump coverage policy, effective January 18, 2026. Billing teams managing CPT codes 62360, 62361, 62362, 62367–62370, and related implantable pump procedures need to review updated medical necessity criteria now.

Aetna's CPB 0161 governs one of the broadest DME-adjacent coverage policies in the Aetna book — implantable and external infusion pumps across spasticity, chronic pain, chemotherapy, and other indications. This update affects over 177 CPT codes, 114 HCPCS codes, and 397 ICD-10-CM diagnosis codes. If your practice or facility bills intrathecal pump implantation, baclofen therapy, or intraspinal opioid infusion to Aetna members, this change touches your workflow.

Quick-Reference Table

Aetna Infusion Pump Coverage Criteria and Medical Necessity Requirements 2026

Aetna's infusion pump coverage policy sets a three-part threshold that applies to every implanted pump claim, regardless of indication. All three conditions must be true before Aetna considers the device medically necessary DME:

That third criterion is where claims fall apart most often. FDA device approval is drug-specific. A pump approved for morphine is not automatically approved for another agent. Document the FDA indication for your pump-drug combination in the record before billing CPT 62360, 62361, or 62362.

Intrathecal Baclofen (CPT 62360–62362, 62367–62370)

Aetna's infusion pump billing criteria for baclofen therapy — used to treat intractable spasticity — require a cascade of documented failures before the pump is covered. The member must have severe spasticity of cerebral or spinal origin. That includes spinal cord injury, multiple sclerosis, stroke, stiff person syndrome, and traumatic brain injury.

One important flag for TBI cases: Aetna follows FDA guidance that members with TBI-related spasticity should wait at least one year after injury before long-term intrathecal baclofen therapy is considered. The policy does not provide an exception to this waiting period.

The member must also require therapy in order to sustain upright posture, balance in locomotion, or increased function. Document that functional need explicitly. It is a required criterion, not supporting context.

The oral baclofen trial requirement is real, with one exception. Adult members must show documented failure or intolerance of oral anti-spasmodics — baclofen, tizanidine, or dantrolene at maximum doses. For children 12 and under, Aetna waives the oral trial requirement. The increased risk of adverse effects from oral baclofen in pediatric patients is the stated reason. Document this clearly if you're treating a pediatric patient.

Before Aetna covers the implanted pump, the member must also show a favorable response to a 100 mcg intrathecal baclofen bolus. A pump for continuous infusion is not medically necessary for members who don't respond to that trial dose. If the bolus trial doesn't produce a positive response, the implant won't be covered. Bill the trial separately and document outcomes before submitting the implant claim.

For anti-spasmodic indications broadly, the standard is a six-week trial of non-invasive spasticity management. That trial must have failed — either inadequate control or intolerable side effects — before the pump qualifies.

Chronic Intractable Pain (CPT 62360–62362)

For intraspinal opioid therapy — morphine, ziconotide (Prialt), or clonidine — Aetna requires a preliminary trial before implanting a pump. That trial covers epidural or intrathecal administration of the opioid or adjunct. Aetna considers a one-to-two-day inpatient stay medically necessary for the trial itself.

The member must have severe chronic intractable pain of malignant or non-malignant origin that hasn't responded to less invasive methods. Systemic opioids must have been tried and found inadequate. The history must reflect attempts to address behavioral and physical factors that amplify pain response.

This is a documentation-heavy indication. Aetna is going to look for a paper trail showing systemic therapy failure before they cover the permanent implant under this coverage policy.

Prior Authorization

The source policy does not explicitly state prior authorization requirements. Consult your Aetna provider agreement and current PA schedules to confirm whether pre-authorization is required for specific codes under CPB 0161. Given the multi-step medical necessity criteria here, submitting documentation of each criterion before the procedure is still a sound practice — but don't assume that satisfying medical necessity criteria alone substitutes for a formal PA where one is required.

Aetna Infusion Pump Exclusions and Non-Covered Indications

The policy is explicit: an implanted pump for continuous baclofen infusion is not medically necessary when the member does not respond to the 100 mcg intrathecal bolus trial. That's a hard stop. A failed bolus trial equals a denied pump implant claim.

Members who haven't exhausted non-invasive options aren't covered either. If oral anti-spasmodics haven't been tried at maximum doses — and there's no documented contraindication — Aetna won't cover the pump. Same logic applies on the pain side: systemic opioid failure is a prerequisite, not a suggestion.

Aetna follows FDA guidance that members with TBI-related spasticity should wait at least one year after injury before long-term intrathecal baclofen therapy is considered. The policy does not provide an exception to this waiting period. If you're billing CPT 62360 or 62361 for a TBI patient, document the injury date and confirm the one-year window has passed before submitting.

Coverage Indications at a Glance

Aetna Infusion Pump Billing Guidelines and Action Items 2026

1. Audit all active intrathecal pump cases before January 18, 2026.
Pull every open or pending claim tied to CPT 62360, 62361, 62362, and 62367–62370. Confirm that documentation supports each of Aetna's three core criteria: drug medical necessity, necessity of the implanted route, and FDA pump-drug approval. Fix gaps before submitting.

2. Verify the FDA indication for every pump-drug combination in your documentation.
This is the most common miss. Your record must show the specific pump is FDA-approved for the specific drug. A physician note saying "medically necessary" is not enough. Pull the device labeling or IFU and attach a reference in the prior auth submission.

3. Update your charge capture for pediatric baclofen cases.
For patients age 12 and under, remove any workflow step that flags a missing oral baclofen trial. Aetna explicitly waives that requirement for this age group. But document the patient's age and the rationale for skipping the oral trial. Missing that note still creates a denial risk.

4. Capture the TBI injury date for every baclofen pump case.
If your patient has a TBI diagnosis in the record, document the injury date explicitly. Aetna follows FDA guidance requiring at least one year post-injury before long-term intrathecal baclofen therapy is considered, and the policy provides no exception to that waiting period. If you're billing CPT 62360 or 62361 for a TBI patient, the injury date needs to be part of the prior auth package.

5. Bill the intrathecal bolus trial before submitting the pump implant claim.
For baclofen cases, use the appropriate code for the 100 mcg trial dose. Document the member's response. If the response is favorable, that documentation becomes the bridge to the implant claim. If it's not favorable, stop — the implant won't be covered. Don't submit both claims simultaneously.

6. For chronic pain cases, bill the inpatient trial stay separately and document systemic opioid history.
Aetna covers a one-to-two-day inpatient stay for the intraspinal opioid trial. Make sure that stay is billed correctly and that the inpatient record reflects the systemic opioid failure history. That history is a medical necessity prerequisite, not just supporting documentation.

7. Loop in your compliance officer if you have high-volume intrathecal pump billing.
This policy covers a wide range of indications, and the criteria cascade is specific. If you bill more than a handful of these cases per month, your compliance officer should review your documentation templates against the updated CPB 0161 criteria before the effective date of January 18, 2026.

CPT, HCPCS, and ICD-10 Codes for Infusion Pumps Under CPB 0161

Covered CPT Codes (When Selection Criteria Are Met)

Note: Sub-descriptions for CPT codes 62360–62362 and 62367–62370 are not confirmed by the CPB 0161 policy text as provided. Consult the AMA CPT codebook for complete code-level descriptions. The full policy lists 177 CPT codes and 114 HCPCS codes. The codes above represent the core implantable pump and catheter CPT codes most directly affected by the updated medical necessity criteria. Review the full CPB 0161 policy at app.payerpolicy.org/p/aetna/0161. for the complete code list.